Researchers develop new, modular strategy for T-cell-based immunotherapy

Share this article The move includes acquisition of ONP-002, a completely synthetic neurosteroid being developed to treat mild traumatic brain injury. Credit: Rocketclips, Inc. /

Young, old and mid­dle-aged peo­ple, fam­i­lies and part­ners are among the new faces of Bausch + Lomb’s glau­co­ma cam­paign de­but­ing Wednes­day. Bausch’s an­nu­al Jan­u­ary ef­fort,

Among patients hospitalized for an emergency general surgery (EGS) condition, primary care follow-up within 30 days of discharge was associated with a significant reduction in